Current developments in the psychopharmacological treatment of childhood and adolescent bipolar disorder

Inal-Emiroglu F. N., Miral S.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.18, sa.4, ss.313-321, 2008 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 4
  • Basım Tarihi: 2008
  • Dergi Adı: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.313-321
  • Anahtar Kelimeler: Bipolar disorder, psychopharmacological treatment, children, adolescents, DEFICIT HYPERACTIVITY DISORDER, PLACEBO-CONTROLLED TRIAL, OPEN-LABEL TRIAL, DOUBLE-BLIND, DIVALPROEX SODIUM, LITHIUM TREATMENT, ACUTE MANIA, CHILDREN, DEPRESSION, SYMPTOMS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Bipolar disorder (BD) of childhood and adolescence is not rare but difficult to diagnose because of its atypical presentation compared with that of adults. Similar to treatment for adults with BD, pharmacotherapy is considered as the first-line treatment for pediatric BD and usually involve the use of mood stabilizing agents such as lithium, carbamazepine, and valproate and antipsychotic agents, such as risperidone, olanzapine, and quetiapine. Sufficient data was not obtained about pharmacotherapy of BD and most of the studies to date do not have standard assessment protocols and placebo control groups. In this article we aimed to review all controlled, open, and special designed studies and to inform about their findings. According to results from published studies: 1- There are few well-designed clinical trials and systematic treatment with prospective follow-up is essential for methodology, 2- lithium and divalproex sodium appear to have comparable efficacy at the end of the trials, 3- some controlled data were obtained for safety and efficacy of quetiapine, 4- stimulants should be used cautiously but are not contraindicated.